BRAF and colorectal carcinoma: Monotherapy with a BRAF inhibitor only yields a response in approximately 5% of CRC patients with the BRAFV600E mutation, which is one of the prominent mutations in approximately 10% of CRC patients (Venderbosch et al., 2014).